Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
10.90
-0.51 (-4.47%)
At close: Nov 4, 2025, 4:00 PM EST
11.10
+0.20 (1.83%)
After-hours: Nov 4, 2025, 5:07 PM EST
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 9 analysts that cover Ocular Therapeutix stock have a consensus rating of "Strong Buy" and an average price target of $22.33, which forecasts a 104.86% increase in the stock price over the next year. The lowest target is $17 and the highest is $31.
Price Target: $22.33 (+104.86%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ocular Therapeutix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 4 | 4 |
| Buy | 7 | 7 | 5 | 4 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 7 | 7 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $14 → $20 | Strong Buy | Maintains | $14 → $20 | +83.49% | Oct 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $19 | Strong Buy | Maintains | $15 → $19 | +74.31% | Oct 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $21 → $31 | Buy | Maintains | $21 → $31 | +184.40% | Oct 3, 2025 |
| Baird | Baird | Buy Maintains $17 → $24 | Buy | Maintains | $17 → $24 | +120.18% | Oct 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +92.66% | Oct 2, 2025 |
Financial Forecast
Revenue This Year
56.17M
from 63.72M
Decreased by -11.85%
Revenue Next Year
66.14M
from 56.17M
Increased by 17.75%
EPS This Year
-1.49
from -1.22
EPS Next Year
-1.41
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.2M | 87.0M | |||
| Avg | 56.2M | 66.1M | |||
| Low | 49.3M | 51.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.7% | 55.0% | |||
| Avg | -11.9% | 17.7% | |||
| Low | -22.6% | -8.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.40 | -1.04 | |||
| Avg | -1.49 | -1.41 | |||
| Low | -1.53 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.